Bibliografía del artículo
1. Food and Agriculture Organization-World Health Organization. FAO-WHO Expert Committee on Brucellosis sixth report. World Health Organization technical report series No. 740. Geneva: World Health Organization, 1986.2. Solera J, Martínez-Alfaro E, Espinosa E. Recognition and optimum treatment of brucellosis. Drugs 1997;53:245-56.3. Young EJ. Brucella species. In: Yu VL, Merigan TC Jr, Barriere SL, eds. Antimicrobial therapy and vaccines. Baltimore: Williams & Wilkins, 1999:71-89.4. Acocella G, Bertrand A, Beytout J, et al. Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. J. Antimicrob. Chemother 1989;23:433–439.5. Montejo JM, Alberola I, Gonzalez-Zarate P, et al. Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. Clin Infect Dis 1993; 16: 671–676.6. Solera J, Espinosa A, Martínez-Alfaro E, et al. Treatment of Human Brucellosis with doxycycline and gentamicin. Antimicrob Agents Chemother 1997;41:80-4.7. Alton GG, Jones LM, Pites DE. Laboratory techniques in brucellosis. Monograph series. World Health Organization (WHO), Geneva. 1975.8. Solera J, Medrano F, Rodríguez M, Geijo P, Paulino J. Ensayo terapeutico comparativo y multicentrico de rifampicina y doxiciclina frente a estreptomicina y doxiciclina en la brucelosis humana. Med. Clin. (Barcelona) 1991;96:649–653.9. De Leenheer AP, Nelis HJ. Doxycycline determination in human serum and urine by high-performance liquid chromatography. J Pharm Sci 1979; 68:999–1002.10. Fleiss JL. Statistical methods for rates and proportions, 2nd ed., John Wiley, & Sons, Inc., New York. 1981: 260.11. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1–39.12. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34:187–220.13. Ariza J, Corredoira J, Pallares R, et al. Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis 1995; 20:1241-9.14. Solera J, Martinez-Alfaro E, Espinosa A, Castillejos ML, Geijo P, Rodriguez-Zapata M. Multivariate model for predicting relapse in human brucellosis. J Infect 1998;36:85-92.15. Lubani MM, Dubin KI, Sharda DC, et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J. 1989;8:75–78.16. Abramson O, Abu-Rashid M, Gorodischer R, Yagupsky P. Failure of short antimicrobial treatments for human brucellosis. Antimicrob Agents Chemother 1997;41:1621-2.17. Ariza J, Gudiol F, Pallares R, et al. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med 1992;117:25–30.18. Ariza J, Gudiol F, Pallares R, Rufi G, Fernandez-Viladrich P. Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis. Antimicrob Agents Chemother 1985; 28:548–551.19. Ariza J, Gudiol F, Pallares R, Rufi G, Fernandez-Viladrich P. Comparative trial of co-trimoxazole versus tetracycline-streptomycin in treating human brucellosis. J Infect. Dis. 1985;152:1358–1359.20. Solera J, Rodriguez-Zapata M, Geijo P, et al. Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. Antimicrob Agents Chemother. 1995;39:2061–2067.